Subscribe
Be the first with the news that moves the market- HYTN Innovations (HYTN) has begun cultivating psilocybin mushrooms under its Health Canada Dealer’s License
- The company has installed state-of-the-art equipment at its Kelowna facility to support the development of Active Pharmaceutical Ingredients
- The company is pursuing Current Good Manufacturing Practice (“cGMP”) certification in Canada and Australia
- HYTN formulates, manufactures, markets, and sells cannabis goods
- HYTN Innovations Inc. (HYTN) opened trading at C$0.10 per share
HYTN Innovations (HYTN) has begun cultivating psilocybin mushrooms under its Dealer’s License granted by Health Canada.
This announcement supports HYTN’s mission to be a leading manufacturer of psychoactive and psychotropic compounds.
The company also announced it has installed state-of-the-art equipment at its Kelowna facility to support the development of Active Pharmaceutical Ingredients (APIs) and strengthen the company’s technological capabilities.
HYTN has also established a partnership with Graeme Staley, founder of Entheopharm Solutions Inc., and Dr. Philippe Henry, enabling the company to commence the development of APIs containing a wide range of compounds.
Jason Broome, HYTN’s Chief Operating Officer, expressed his confidence in the company’s capability to meet API-level specifications for psilocybin, as well as other psychoactive and psychotropic compounds.
“With the necessary licenses, systems, and expert personnel, HYTN is well-positioned to develop a diverse portfolio of APIs. The company’s historical success commercializing novel formulations showcases our understanding of the regulatory systems in which we operate.”
To meet global standards, the company is pursuing Current Good Manufacturing Practice (“cGMP”) certification through both the Canadian and Australian health authorities. Pending cGMP accreditation, HYTN will concentrate on producing high-quality psilocybin extracts, expanding its cannabis product lines, and refining approved substances.
HYTN’s Chief Executive Officer, Elliot McKerr, stated,
“The company remains committed to expanding its product offerings and leveraging its manufacturing site and quality systems. HYTN is confident in its ability to achieve cGMP certification and become a leading producer of high-quality APIs worldwide. HYTN’s nationally and internationally listed cannabis products, featuring Elevation Technology®, will remain a cornerstone of its strategy. These products are available in both medical and recreational marketplaces and are known for their superior bioavailability, quality, and consistency.”
HYTN formulates, manufactures, markets, and sells cannabis goods.
HYTN Innovations Inc. (HYTN) opened trading at C$0.10 per share.
